DBV Technologies’ June 6th 2012 Ordinary Meeting of Shareholders

Adoption of all resolutions submitted to the vote of Shareholders

BAGNEUX, France, 6 Juin 2012 - The Ordinary Shareholders’ Meeting of DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, chaired by Pierre-Henri Benhamou, Chairman and Chief Executive Officer, was held today in presence of the Board of Directors and the Company’s Executive Committee.

The Shareholders’ Meeting approved all the resolutions submitted by the Board of Directors and in particular the appointment of Maïlys Ferrère, Investment Director at FSI, as Board observer - as well as the appointment of Didier Hoch as Board member - representing the Fonds Stratégique d’Investissement (‘FSI’).

During the Meeting, Pierre-Henri Benhamou and David Schilansky, Chief Financial Officer, presented - in particular - the major events and financial results for 2011 as well as the most important events since the beginning of 2012.

Pierre-Henri Benhamou, Chairman and CEO of DBV Technologies said: ‘I am delighted to have the FSI, represented by Maïlys Ferrère and Didier Hoch join our Board of Directors. I also wish to warmly thank Mette Agger and Flemming Pedersen for their contribution and their perpetual support to DBV. Today, with a further reinforced shareholding structure and a busy and promising period ahead of us, I am convinced that DBV has all it takes to become the next leader in the treatment of allergy.”

About DBV Technologies:

DBV Technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. DBV Technologies has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. The Viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient’s tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. The company’s significant development program has taken this revolutionary method through to the industrial stage in Europe, initially. The product’s clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. DBV Technologies is focusing on food allergies (milk and peanut) for which there are currently no effective treatments. It has developed two products: Viaskin® Peanut and Viaskin® Milk. The developmental clinical program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration. The company will subsequently develop a Viaskin® patch for young children with house dust mite allergy – a true public health issue because this pathology is one of the main risk factors for childhood asthma. DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com.

CAUTION: Viaskin® is not approved for sale in the USA.

Contacts

David Schilansky
Chief Financial Officer
DBV Technologies
Tél. : +33(0)1 55 42 78 75
david.schilansky@dbv-technologies.com

NewCap.
Financial Communication and investor relations
Emmanuel Huynh / Alexandra Schiltz
Tél. : +33(0)1 44 71 94 94
dbv@newcap.fr

Ronald Trahan, APR
Press relations
Ronald Trahan
Tél. : +1 508 359 4005
rctrahan@ronaldtrahan.com